{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:36:33Z","timestamp":1766504193873,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006727","name":"Hochschuljubil\u00e4umsstiftung der Stadt Wien","doi-asserted-by":"publisher","award":["H-319615\/2019"],"award-info":[{"award-number":["H-319615\/2019"]}],"id":[{"id":"10.13039\/501100006727","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"Background<\/jats:title>Late antibody-mediated rejection (ABMR) after kidney transplantation is a major cause of long-term allograft loss with currently no proven treatment strategy. Design for trials testing treatment for late ABMR poses a major challenge as hard clinical endpoints require large sample sizes. We performed a retrospective cohort study applying commonly used selection criteria to evaluate the slope of the estimated glomerular filtration rate (eGFR) within an early and short timeframe after biopsy as a surrogate of future allograft loss for clinical trials addressing late ABMR.<\/jats:p><\/jats:sec>Methods<\/jats:title>Study subjects were identified upon screening of the Vienna transplant biopsy database. Main inclusion criteria were (i) a solitary kidney transplant between 2000 and 2013, (ii) diagnosis of ABMR according to the Banff 2015 scheme at &gt;12 months post-transplantation, (iii) age 15\u201375 years at ABMR diagnosis, (iv) an eGFR &gt; 25 mL\/min\/1.73 m2<\/jats:sup> at ABMR diagnosis, and (v) a follow-up for at least 36 months after ABMR diagnosis. The primary outcome variable was death-censored graft survival. A mixed effects model with linear splines was used for eGFR slope modeling and association of graft failure and eGFR slope was assessed applying a multivariate competing risk analysis with landmarks set at 12 and 24 months after index biopsy.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 70 allografts from 68 patients were included. An eGFR loss of 1 ml\/min\/1.73 m2<\/jats:sup> per year significantly increased the risk for allograft failure, when eGFR slopes were modeled over 12 months [HR 1.1 (95% CI: 1.01\u20131.3), p<\/jats:italic> = 0.020] or over 24 months [HR 1.3 (95% CI: 1.1\u20131.4), p<\/jats:italic> = 0.001] after diagnosis of ABMR with landmarks set at both time points. Covariables influencing graft loss in all models were histologic evidence of glomerulonephritis concurring with ABMR as well as the administration of anti-thymocyte globulin (ATG) at the time of transplantation.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Our study supports the use of the eGFR slope modeled for at least 12 months after biopsy-proven diagnosis of late ABMR, as a surrogate parameter for future allograft loss. The simultaneous occurrence of glomerulonephritis together with ABMR at index biopsy and the use of ATG at the time of transplantation\u2013likely representing a confounder in pre-sensitized recipients\u2013were strongly associated with worse transplant outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.817127","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T07:16:50Z","timestamp":1650525410000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Early Estimated Glomerular Filtration Rate Trajectories After Kidney Transplant Biopsy as a Surrogate Endpoint for Graft Survival in Late Antibody-Mediated Rejection"],"prefix":"10.3389","volume":"9","author":[{"given":"Anita","family":"Borski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kainz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Kozakowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Regele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Kl\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Strassl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gottfried","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Fa\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Wenda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u017deljko","family":"Kiki\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Bond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Reindl-Schwaighofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina A.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Eder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Wahrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Haindl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Doberer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg A.","family":"B\u00f6hmig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farsad","family":"Eskandary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1111\/tri.13964","article-title":"The evolution of histological changes suggestive of antibody-mediated injury, in the presence and absence of donor-specific anti-HLA antibodies.","volume":"34","author":"Coemans","year":"2021","journal-title":"Transpl Int."},{"key":"B2","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/tri.13436","article-title":"The therapeutic challenge of late antibody-mediated kidney allograft rejection.","volume":"32","author":"Bohmig","year":"2019","journal-title":"Transpl Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1056\/nejmra1802677","article-title":"Antibody-mediated rejection of solid-organ allografts.","volume":"379","author":"Loupy","year":"2018","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMra2014530","article-title":"Long-term survival after kidney transplantation.","volume":"385","author":"Hariharan","year":"2021","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients.","volume":"17","author":"Choi","year":"2017","journal-title":"Am J Transplant."},{"key":"B6","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1681\/ASN.2020071106","article-title":"A randomized clinical trial of anti\u2013IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection.","volume":"32","author":"Doberer","year":"2021","journal-title":"J Am Soc Nephrol."},{"key":"B7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1600-6143.2011.03525.x","article-title":"Summary of FDA antibody-mediated rejection workshop.","volume":"11","author":"Archdeacon","year":"2011","journal-title":"Am J Transplant."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1111\/ajt.13347","article-title":"Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.","volume":"15","author":"Wiebe","year":"2015","journal-title":"Am J Transpl."},{"key":"B9","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/TP.0000000000003274","article-title":"Change in estimated GFR and risk of allograft failure in patients diagnosed with late active antibody-mediated rejection following kidney transplantation.","volume":"105","author":"Irish","year":"2021","journal-title":"Transplantation."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4923","article-title":"Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study.","volume":"366","author":"Loupy","year":"2019","journal-title":"BMJ."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1111\/ajt.12478","article-title":"Class II HLA epitope matching \u2013 a strategy to minimize de novo donor-specific antibody development and improve outcomes.","volume":"13","author":"Wiebe","year":"2013","journal-title":"Am J Transpl."},{"key":"B12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the national kidney foundation in collaboration with the US food and drug administration and European medicines agency.","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ajt.14107","article-title":"The Banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology.","volume":"17","author":"Loupy","year":"2017","journal-title":"Am J Transpl."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 kidney meeting report (I): updates on and clarification of criteria for T cell\u2013 and antibody-mediated rejection.","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transplant."},{"key":"B15","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","article-title":"Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values.","volume":"53","author":"Levey","year":"2007","journal-title":"Clin Chem."},{"key":"B16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD.","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1097\/01.tp.0000441091.47464.c6","article-title":"Complement component C3 activation: the leading cause of the prozone phenomenon affecting HLA antibody detection on single-antigen beads.","volume":"97","author":"Schwaiger","year":"2014","journal-title":"Transplantation."},{"key":"B18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1681\/asn.2017070818","article-title":"A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection.","volume":"29","author":"Eskandary","year":"2018","journal-title":"J Am Soc Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1093\/ndt\/gft355","article-title":"When do we need competing risks methods for survival analysis in nephrology?","volume":"28","author":"Noordzij","year":"2013","journal-title":"Nephrol Dial Transplant."},{"key":"B20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/tri.13081","article-title":"An unjustified benefit: immortal time bias in the analysis of time-dependent events.","volume":"31","author":"Gleiss","year":"2018","journal-title":"Transpl Int."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14326","article-title":"Defining a minimal clinically meaningful difference in 12-month estimated glomerular filtration rate for clinical trials in deceased donor kidney transplantation.","volume":"35","author":"Mayne","year":"2021","journal-title":"Clin Transplant."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1097\/TP.0000000000002961","article-title":"Late graft loss after kidney transplantation: is \u201cdeath with function\u201d really death with a functioning allograft?","volume":"104","author":"Gaston","year":"2020","journal-title":"Transplantation."},{"key":"B23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.kint.2020.07.025","article-title":"Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation.","volume":"99","author":"Raynaud","year":"2021","journal-title":"Kidney Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1681\/ASN.2015050524","article-title":"Relationship between eGFR decline and hard outcomes after kidney transplants.","volume":"27","author":"Clayton","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1600-6143.2009.02954.x","article-title":"Pathological and clinical characterization of the \u2018troubled transplant\u2019: data from the DeKAF study.","volume":"10","author":"Gourishankar","year":"2010","journal-title":"Am J Transplant."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1681\/asn.2016070797","article-title":"Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients.","volume":"28","author":"Aubert","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.kint.2017.03.015","article-title":"Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes.","volume":"92","author":"Allen","year":"2017","journal-title":"Kidney Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1016\/j.transproceed.2016.08.011","article-title":"Recurrent IgA nephropathy after kidney transplantation.","volume":"48","author":"Nijim","year":"2016","journal-title":"Transplant Proc."},{"key":"B29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2215\/CJN.08970719","article-title":"Recurrence of FSGS after kidney transplantation in adults.","volume":"15","author":"Uffing","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/jama.2020.1267","article-title":"Why test for proportional hazards?","volume":"323","author":"Stensrud","year":"2020","journal-title":"JAMA."},{"key":"B31","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/ajt.14520","article-title":"Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: a multicenter, prospective, randomized, double-blind clinical trial.","volume":"18","author":"Moreso","year":"2018","journal-title":"Am J Transpl."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.2215\/cjn.09901014","article-title":"Capillary C4d and kidney allograft outcome in relation to morphologic lesions suggestive of antibody-mediated rejection.","volume":"10","author":"Kiki\u0107","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13113-5","article-title":"Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants.","volume":"10","author":"Koenig","year":"2019","journal-title":"Nat Commun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/s0140-6736(18)32473-5","article-title":"Contribution of non-HLA incompatibility between donor and recipient to kidney allograft survival: genome-wide analysis in a prospective cohort.","volume":"393","author":"Reindl-Schwaighofer","year":"2019","journal-title":"Lancet."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.817127\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T07:16:56Z","timestamp":1650525416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.817127\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":34,"alternative-id":["10.3389\/fmed.2022.817127"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.817127","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,4,21]]},"article-number":"817127"}}